Hepatic Safety Profile of Vildagliptin 100 mg SR - Ft. Prof. Dr Aravinda Jagadeesha

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-11-26 07:03 GMT | Update On 2023-05-03 07:31 GMT

Vildagliptin has established its efficacy over the years by displaying significant HbA1c lowering accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy as well as newer formulations like sustained release.

Several studies have also focussed on establishing safety parameters of Vildagliptin.

In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr Aravind's Diabetes Centre in Bengaluru, India talks about how Vildagliptin as a molecule has proven itself in the past 15 years and provides his insights on the hepatic safety profile of Vildagliptin 100mg SR.

Dr Jagadeesha specifically alludes to a pooled hepatic safety analysis, in which it was seen that there was no overall increased risk of persistent transaminase elevations with concomitant bilirubin elevation greater than the upper limit for either vildagliptin dose.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Hepatic Safety Profile of Vildagliptin 100 mg SR - Ft. Prof. Dr Aravinda Jagadeesha

Similar News

What's Putting India at Risk for Diabetes and Obesity? ICMR Study Reveals the Hidden Dietary Culprit

Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

Mango Consumption Linked to Improved Metabolic Health and Diabetes Prevention: Study

The Silent Killer in MASLD? It's Not Diabetes, Says New Study

Study Reveals Why Some People with Obesity Avoid Disease Through Genetic Mapping

Enhanced Efficacy of High-Dose Semaglutide in Obesity and Type 2 Diabetes: STEP UP Trials Find

Smoking Raises Risk for All Type-2 Diabetes Subtypes, Especially Severe Ones: Study

Only 1 in 5 People with Diabetes Have Optimal Blood Sugar Control: Study Finds